Health Care·April 30, 2026
BridgeBio Pharma (NASDAQ: BBIO) Maintains Upside as Analysts Boost Price Targets
BBIO rose 0.24% with three analysts raising or maintaining Buy ratings and price targets ranging from $100 to $106.
BridgeBio Pharma Inc. (NASDAQ: BBIO) Stock News & Analysis
BridgeBio Pharma Inc. (NASDAQ: BBIO) is a company in the Health Care sector, listed on the NASDAQ. This page collects all Alpha Stocks Insight coverage of BBIO: earnings reports, analyst actions, and company news, updated as new articles are published. 3 articles since April 30, 2026.
BBIO Coverage -- 3 Articles
Earnings Report·May 7, 2026
BridgeBio Pharma (NASDAQ: BBIO) Beats Revenue Guidance as Attruby Drives Growth
BridgeBio's Q1 revenue surge powered by Attruby sales beat estimates, though EPS missed—stock authorizes $500M buyback.
4 min readRead article
Health Care·April 30, 2026
BridgeBio Pharma (NASDAQ: BBIO) Rallies on Analyst Confidence Ahead of Q1 Results
Shares gain as three major analysts maintain buy ratings and raise price targets, citing Attruby's commercial promise.
Important Legal Disclaimer
This is for informational purposes only and is not financial, investment, or tax advice. Past performance is no guarantee of future results. We are not licensed advisors. For Swiss residents: This does not constitute a public offer under FINSA. For EU residents: Not MiFID II compliant advice. For US residents: Not SEC-registered advice. Always consult a qualified professional. Investing involves risk of loss.
Affiliate disclosure: This site may contain affiliate links to brokerage platforms. If you open an account through one of our links, we may earn a commission at no additional cost to you. Affiliate relationships do not influence our editorial content or stock coverage decisions.